Compensated Awareness Post View
Disclaimer
RBCC Pursues JV Involving Revolutionary Breakthrough in $60 Billion Drug Delivery Market
Rainbow Coral today announced that its biotech division, Rainbow BioSciences, is currently in talks to help develop and market a revolutionary, sustained-release drug delivery platform that could soon enable safer delivery of biologic agents and small molecules, while also increasing efficacy and convenience to a whole new level.
Specifically, a joint venture agreement with a privately held drug delivery company developing the novel technology is on the table. The local delivery platform is being developed to address the issues posed by systemic drug delivery, including oral and IV delivery. Often systemically delivered drugs can’t reach sufficient concentrations in target organs to be effective without damaging the liver, kidneys, or heart. Systemic delivery also requires frequent, expensive injections in many cases.
The technology Rainbow BioSciences is currently reviewing could enable selective, site-specific delivery, allowing for lower drug concentrations and greatly reducing the risk of drug toxicity.
“Because it’s a sustained-release delivery system, patients could potentially only need one injection every six months,” said RBCC CEO Patrick Brown. “In addition to helping millions of patients struggling with chronic conditions, the technology also has the benefit of extending the patent life cycles of drugs, giving potential pharmaceutical partners a tremendous market advantage.”
“RBCC hopes to conclude its due diligence work on the drug delivery company and sign a joint venture agreement to begin getting the new technology into doctors’ hands in the next few weeks,” Brown added.
For more information on Rainbow BioSciences, visit www.rainbowbiosciences.com
